Amarin Pharma
Coverage of Amarin Pharma in the Nexus archive.
- Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products
The Supreme Court unanimously ruled that generic drug manufacturer Hikma Pharmaceuticals cannot be held liable for patent infringements by branded drugmaker Amarin Pharma, rejecting claims that Hikma's labeling, press releases, and website statements actively induced infringement. The case centered on whether Hikma's generic version of Vascepa, used interchangeably with Amarin's patented drug for cardiovascular and hypertriglyceridemia treatments, could be blamed for doctors and pharmacists using the generic for patented purposes.
- Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
The Supreme Court ruled that Amarin Pharma has not sufficiently proven that Hikma Pharmaceuticals' generic version of icosapent ethyl (Vascepa) infringes on its patents. The decision centers on a 'Skinny Label' case involving the heart drug.
- Supreme Court rules on fight between drugmakers in "skinny label" patent case
The Supreme Court ruled in favor of a generic drugmaker accused of infringing Amarin Pharma patents related to 'skinny labels.' The decision was reported by CBS News' Jan Crawford.